Illumina (ILMN) 28 Nov 182007 Q1 Earnings call transcript

Company Profile

Participants

Jacquie Ross	VP, IR
Sam Samad	SVP and CFO
Ross Muken	Evercore ISI

Call transcript

Due to licensing restrictions, you must log in to view earnings call transcripts.

Ross Muken

Hello and welcome everyone. Thanks for joining us here at sort of our inaugural HEALTHCONx Conference here in Boston.

As many of you know, I’m Ross Muken, I run the Life Science Tools & Diagnostic Product here at Evercore ISI. It’s my pleasure having with us a company I’ve known for a long time and an individual who I’ve been getting to know quite well over the last year or so, since joining Illumina, Sam Samad, who is our CFO; and then in the back, we have Jacquie, who all of you know does a fantastic job on IR.

So Sam has some exciting news to start with.

get some formalities, of you can that let into get the I’d through so the we So questions.

Sam Samad

Yes, the so Safe is Harbor. the exciting news

comments statements. So could been asked remind that I’ve to include my forward-looking you today

for here of commercial You should SEC protected from under Biosciences XXXX. today’s having results and statements our for in by today that refer our our in the our with activity current And that cause Private Reform results inviting differ here. Pacific is Act us thanks regarding in entirety be will the our all Securities is me be Also a could intent of will filings uncertainties to Litigation SEC and risks for the to its that made future. the discussion discussed and thanks the materially expectations. financial statement filing proxy presentation information the qualified It forward-looking Ross

Ross Muken

Very done. nicely

would on you since mainly So to that gave a the disclosure reasonable place start. PacBio probably us be

guess how presence given think see I box. and [ph] family, and read. guess, they I starting kinds obviously sort sort sort read, of long into in clinical think as there Illumina a this to cost inflection, short seems of about be transaction, complementarity like you your gets through primarily go business as it about they you it into key where to attractions, of their the think the were you can the and where proposed you fits of what in the So were

into about being flavor are of sort asset you the us hopefully Illumina that of family. thinking Just give brought sort how the for

Sam Samad

acquiring month all or acquisition this or reorient of this a Biosciences so this I’m and of know this of long about Pacific you or earlier share excited transition acquisition, we’re about really we just you $X.X Yes, technology. of approximately group, and the now a for really that by Sure. to price the $X you billion announced know most to excited sure read

are there long said, really where you some important. definitely applications, complimentary is As read

Let me some let just acquisition. background clarify a things just me give on and this few

brings. First all, the choice like of you the where sequencing. most costs, explain And complimentary you complimentary based this, the going be continue really to applications. of sequencing for short benefits that will capability, we pharmacogenomics, some those as important really short-read applications have of a read absolutely to -- lead it’s continue applications technology technology sequencing like platform said the need genome, accuracy. functional applications that important SBS-based parts becomes choice read on technology to platform SBAs It’s repetitive believe Having there are to higher long where long be genomics read of to in some a

that an benefits what not with today has. read Illumina it’s competes it’s sequencing, to So short but application very complimentary

two so or the with pretty established they have some last long months genome in made eyes XX% the became say. have able now, they technology that has higher of if the background for it for been the a they path as have really of PacBio is for their read degree sometime; of accuracy But three read is things. well. established reason One establish couple of same $XXXX this, impressive [ph] I now And which the accuracy consensus progress had said the on that’s to evaluating that at impressive. important terms is developed to as And time, technology been something we’ve needless something this long and technology obviously not a We’ve sometimes. in is to been there’s has of very that I mean you our -- about think

bringing two the come today, we first to continued think markets. development those we and play applications the combination this with clinical bring about the both roadmaps We of PacBio, technology. for the short both advance don’t of also together, accelerate Illumina’s read And, acquisition discovery of can insights because existing we also read technologies functional read companies brings of So also can the and some and their you’re markets innovation certain some out us what microbiology, you’re of can terms in of benefits scientific cost and together, we that to you’re has And in expertise you – all pharmacogenomics, really again in down. two say that of complimentary sets we we both think of of we long expertise insight. there best bringing lot those bringing of they engines expand can terms technology bring markets, a as in bring would where the said companies I expand genomics I long clinical when

Ross Muken

and do technologies of long had obviously a And, on animal some today and different newer in that the of read you approach? you elements that in sort a just the sort from a competitive how competitive of sort evolve that different read, How short of landscape those long of been technological you think have based of you do market sort do number How A distinct of approaches lot pieces. etcetera. slightly will nanopore planned of read focus had area. think different think about

Sam Samad

market in time. so now along expects or to how five talk and in PacBio maybe can is the back we two first read step and competitive market of to million speak. overall some mean, the long so talk I what are the grow years’ about forces half then approximately about those to XXX this read, today, and so overall Yes, about and -- right a billion

of rate XX%. growth compounded a So

competitive mean, plan we’ve the We’ve in those of technology where at we brings If applications investment long As very I complementary there’s believe in the I Oxford Ross, read Nanopore. competition, think out obviously in the that in terms read a know And we today, benefit. past competitor we terms is space said, least them the the but long are – or don’t technology biggest that evaluated had we’ve a there made. of Nanopore; about in Nanopore. important I Oxford Oxford progress

some And advantages to so, bring table for the sure. they

one the think say, to an the They still they would space. advancement established accuracy player read level a PacBio area has. important is and have are of I not that gotten the they in definitely same accuracy. PacBio I here improving long haven’t the are But that

Ross Muken

So maybe of pivoting the right. the business, base sort

has year you seen sort really how an versus think as and markets enabled last and customer of transformative the certainly the So, NovaSeq I investor compare us tremendously iteration cadence you our The qualitatively look evolution maybe sort then been would that from maybe more a is of is how expectations. number at you to and kind year, box adoption of probably the of of going type not of to guess, these next markets. work, of of of perspective you’ve sort this momentum. into adoption this we’ve contrast to new start gain as that of qualitatively box some some take exceeded

Sam Samad

SX varied high to expanding instruments, see a has in by of cell, NovaSeq, that comes of that No has to also by the with which the important point SX Sure. NovaSeq We customer there that and flow will by we happened utilizes and cells. about really more this how terms flow think it customer base happened flow the we I democratizing really of that customers. launched happened that’s question, chance, design, design with high that, we started throughput that launched NovaSeq and launched is access throughput not sequencing, started you towards cell. these XXXX, Then a QX high intent it’s important is utilization more out; geared pool after journey we’ve When much instruments. was really the really throughput the in

high cases which the that launched those I When instruments, And running customers mean HiSeq X customers, SX some I -- in very lower HiSeq When convert HiSeq lower the but lower than days. still say then towards spectrum, I about instruments. level that from is are So, think would throughput of to it’s SX, on more the end throughput work. of the X throughput of evolution the looking the we say running customers. we early after geared still

end NovaSeq of so taken have XXX at actually their the HiSeq customers XXXX. or we vessels of XX% back first in the XXXX, of only As at on X said end the

NovaSeq. dated little tell still customers in actually you but to there’s was that But very you early about you NovaSeq. fully that know about when early can So we’re talking think journey. even bit very a terms in this that I’m a not still even is still, converting of today, days ordering

different varied also flow base in completely customers We’re know NovaSeq. what upgraded are using they still with still very to few is you of terms very And, cells. that customer have

cell terms In mean [ph] we looking also the out. forward, of SX coming have I flow

to to future, lower even it to SX, throughput the flow spectrum. at in point so lower and also out on come expect throughput those going some We be customers some appeal it the will of well as the that’s high cell throughput than

been of democratization want for in customer one certain a we that number, of time, the this one appealing diversity utilization types. you to very has number us is that captures entire give kind base, the the you that to target byproduct pull-through such to different do, continue customer challenging give And this you this work have many see on at varied so what because been that on depending NovaSeq it’s it’s a point of reasons base. hard that flow number it’s to And of And to cells. customer the

Ross Muken

sort will traditional we of consumer and again there us volume through should versus that think where obviously customer, happens How or that pull-through, influence is new the NovaSeq base of in a transition? sort contemplating about because a unique think high the conversions, the that’s of adopters what will a X the very help terms just customer,

Sam Samad

my that that that not them that’s XX customers made fact upgrade time X, to the take reason It’s the expect going have driven or very early customers of is past, previous of want customer is to where upgrade. say NovaSeq, this in few are we to of the cycle few again, customer the multi-year driven comments but them. be them going consistent to upgraded I to our going And HiSeq a customer bought we to by have have A so running with very necessarily that days. hey lot timing, would this So by entirely a time. still back of by it’s comment -- transition. driven take this we preferences, The is NovaSeq,

haven’t and or that some have NovaSeq. running, quarter, this not validated work the on or by NovaSeq customers, entirely in validated work work driven some by because their they it’s really started customers upgrade new are on projects it’s have NovaSeq Now the and that on quarter driven flows particular

Some are then fully HiSeq running have not NovaSeq. a and X of transitioned to NovaSeq but combination

So it’s some customers and depending they’re in those on that sitting of are where the samples running. workflows

Ross Muken

of in the growth How other? disease. new those enabled opportunities some about based sort new that some applications. sequencing areas where the the has characterize thinking I and some thinking of that would are rare each So come vis-à-vis I’m applications relevant population of are to of size maybe thinking are I’m consumable of new areas cost guess, the oncology of curve some thinking and driving you how you the those of etcetera, about we are being of down. the where about growth. comparative sequencing kind

Sam Samad

yes. Sure,

the have one have of sequencing I vectors a couple them. driven And covered, you’ve hit there, area driving some have that NIPT talked that XX% consumables XX% few exciting of whereby seen growth, think seeing quarters, would we of risk in momentum. terms NIPT last an out is usage. as of in of NIPT really We’re over coverage our risk say that as exciting where that we’ve of I a I growth are average and we NIPT expansion about we’ve on high seen terms coverage. have well, lot of -- we have we mean, that

that’s growth vector NIPT Solution that lot bit NIPT bit space more Europe a exciting. key coverage growth, have of and mid area, oncology and throughput VeriSeq enhancing create that throughput seeing you a When and of consumables. a really around been our other risk. the and But average definitely we of we’re of has we in the key vector other think key also focus the believe a sequencing of in momentum that’s migration, also space. mid in So been a about And

climate And the has so, say more would reimbursement positive really a looked I recently. lot

payers four recurring cancer. got and like You’ve presence to Anthem cover of deciding panels cancer lung metastatic in stage

driving also really reimbursement that some terms important there’s advancements so of sequencing consumable potential is And in usage.

the RUGD You’ve about development seeing whole by potential the The also talked important we’re standard-of-care and an $XXXX for to space for CMS RUGD part is a disease. sequencing got good that migrate of for as space. issue to seeing coverage you price in decision in we’re that private with recent undiagnosed genome

population sequencing like, placements But of key growth. say and future been the most a sequencing consumables in that exciting will complete also year has immediate future a will that. the collaboration population been growth, which one potentially area drive that’s that’s expect well initiatives future growth, and GeL very there’s with but interest of future genomes and vector. XXX,XXX mentioned towards the another we we in this on initiatives I its You been of GeL growth and genomics, expect vector that’s a say terms current I would as revenue impact wouldn’t sequencing

Ross Muken

you sort progressive the is breadth do curve what on recently to of see to starting moving population and based of technologies. up. fell of that, of slightly all the typically maybe we’ve be leaving, Helix the some you around in with yours what going of given that almost surprised say geographies you action the sort the but the U.S. in are until these on little we individual parts bit little ahead prior us behind, of of And how been and approaches, and of bit always U.S are hopefully of ahead think was May actually with may could at are partner might other far kind actually us countries and still some catch forward [ph] they we’re Just surprising or and do, a to world of trying a

Sam Samad

even one Cancer not Moonshot they we’re honestly sure that the in cases, very I’m has progress Yeah. look at mean word. pleased there’s U.S. is I the surprise U.S. initiative where population lagged mean, outside And with was if the behind, though the some the seeing I sequencing. the been area

a of The all you a that’s really sequencing important mentioned XX the million the samples other is part over the you’ve so years. genome us next type development looking at taking of and know course

initiatives. medicine an huge, those countries, undiagnosed the countries. But a could and I is initiatives now a I other point want was advanced yeah, migrating some point, We’ve okay, done start good expand England Genomics to of But, standard-of-care genomics. as the don’t been practice into NHS diminish think and GeL work a of your start there’s of initiative, And completion that, cancer Australia the That, is precision that’s to like which even parts progress. say because key about yet, the into population which developing that’s and starting So level, those at some ago, really maybe that in clinical we’re been this seen an which merit see a important XXX,XXX initiative the world Bangladesh, to population an to countries has looking for going the all. the reference been managing it which and to in of samples pleased few to for be for in disease. diagnosing understanding in would and and be announced some I they’ve where at precursor to progress I benefits with that a towards it at the really and of sequencing some we’ve the other genomics talked a genomics of initiative. those say, initiative rare years population think has has we’ve

Ross Muken

how pays kind flipped minute. upfront going you payer diseases it bring do Wait you data these to be evolution all market I’m essentially of feel the preventative of informed There’s payoff on. guess, even laying driven but broadening a individuals university in of of the -- part or where eventually if more earlier to for merits the this an being from next really of a or there some types does out and for more and expense, might if a be that you it’s is being small has population could have phase projects more see it see were U.S. my kind informed more regular a guess population the that babies level you or next than all where from recently utilizing like because to out, iteration what the standard-of-care that’s within that certain of of it I get do my of I becomes applications the understand. percentage starting have it. they’re kind that the the toward born PopSeq more sort And a clinical all in switch of

Sam Samad

Yes, that actually exactly of this that’s to translates that practice and I as fact to key, sequencing benefits the clinically these well, certain will point, will and the medical health yield that know is genomic type demonstrate. does both economic benefits how key knowledge economically practice clinical think obviously populations you the of the in studies

that’s think getting this. has interpretation completed talk to stage the of back genomes. And into as advanced the I towards again the But they’re the part well in of to essentially where easiest it’s becomes because completing yet, fact going that’s but data phase, clinical it Again, for midst towards, the the the this GeL next been and said, the that now of all and practice. one, goal. in analyzing a that XXX,XXX not from I I XXX,XXX they’ve they’re precursor they’re is they’re about, completed the good go most

are is are GeL But systems I key is at in health I’d the maybe So follow to are what the how the demonstrated -- what say precursor the keep is GeL for the to this clinically think which and done burdensome obviously initiative the that battled have and significant mind odyssey children, for clinical diagnostic not economically I building benefits good to model. obviously point demonstrated. as the clinical has terms proof in going instance, of families also a And the practice. is some mean, are child that other that’s through, you points of also important these healthwise, diagnostic look and about stage and when well. think but insights. what but benefits scope all pain effect, and you the clinical into can of insights odyssey, disease that economic that demonstrate see next becomes them are the what with that And RUGD that’s been really families when these and that the of of health taking just that I part a that go

Ross Muken

what struggle will path And spend is think something a we child possible seven early three small possibly, be groups many side figured even so where in make have that to that legacy is the it identify some in progress might with this months see have the technology years with someone or out or has benefits six treatment what patient disease existence. prior could you sequencing the five, of because you to rare where where with answer you we truly of the first it disease is of of

Sam Samad

very diagnosed a another they in have disease children like a had. we Ross. big have complications prevented daily this oncology is that I examples, would stories, it and see right of have in giving I simple dose and other have could where diagnosed of you rare misdiagnosed patient can is and area. have powerful areas But that lot absolutely and been – some compelling obviously, vitamin You’re you them solution really undiagnosed like and Yes. think mean,

tell they is of which trial also only through more And to there the the trendsetters of of in unique working diagnosing trial have patients. lot looking or of, record demonstrated out of a in at stories. way the was that patient can these like economic time. discovered with of there And was important so we’re RUGD of and no way demonstrating Children’s And sequencing. I say, that how rare some benefits benefits -- health Hospital diagnose, And HiSeq we Rady would than is and that have some disease a pacesetters undiagnosed terms benefits

Ross Muken

that of also are of maybe the upon touched and not thinking you so and emerging guess huge just areas; but opportunity? we just test, are you some diagnostic these liquid is a growth about finishing some efforts kind made And particularly in the biopsy screening a progress promise, how of with of there oncology, where I evolution

Sam Samad

far players Yes. Guardant, also I there's some with lot so there’s and both in good made that so been space. a and with mean, GRAIL of Freenome progress with

with done, no very it lot There's the out mean, Illumina I for results also a of liquid -- others. think becomes as platform there, that days, necessary liquid I in some of growth insights some yield biopsy. do as of early platform and sequencing sequencing really these for I terms the not because NovaSeq really can't of of the that critical. where Its of human potentially for with critical, improve there say to necessarily wouldn’t that in that still be in but of GRAIL important, would can to characterize it’s work but some I very it’s amount potential health. the better a NovaSeq can think throughput, there's benefit really patients and and frankly that I out bring, And better bring than done needs space allowing to be biopsy high deep studies

Ross Muken

audience? do just have just All the of talking any I you’re to time Maybe high right. us side to the obviously see, things. Help translate wanted the CFO of lot questions about those, financial in in spent throughput side. we we

in terms what we do the the guidance, next growth kind to obviously high-end high-end levels and you into of portfolio? off dynamics the So kind not consumable of jump has more the as been I roughly of in but sort to need we of year next year. give a guess us I’m at used for seeing least of where for been growth sustain flavor at asking to

Sam Samad

into financials. yes, So, the go I won’t obviously

guidance. haven’t given XXXX We

sequencing and a pull-through specific NovaSeq, pull-through sequencing of But So record for growth utilization this by is. year though which strong percentages of the record on terms by utilization that been about but I a speak driven year on and in NovaSeq. has another way to consumable QX we’re consumables we NovaSeq, the can’t that introduction pull-through we haven’t in had on NovaSeq we NovaSeq. asked QX number on what number even given constantly had the In

over I sequencing we sustained next going consumables we what’s NovaSeq been we consumable definitely, we and all has of said before, said consumables You me transition as additional in expect say periods when a on the that's not borne that ramp think a about I’ve to then forward, but consumable. HiSeq transition as number that's growth sequencing with we first talk the I areas consumables the So, me course X would continue would NovaSeq that directionally we’ve to on that, that out potentially a as When of directionally, see months. years, and let over catalyze offset additional as take will talk lot applications, of down of few XXXX utilization by which HiSeq continues mean, growth let that is we’ve expect of driving number direction? know, coming about expect a up, drive seen

sort So, momentum. of that’s the overall

transition, that’s but overall going every to some overall will quarter that direction, doesn't the that necessarily percent see consumer because growth X single is depending mean that of Now be choppiness on you trend. that in

although areas that? I oncology and It's vectors rare testing, going because XXXX driven about we mentioned so the these research, before, road of but of are to disease time growth I be so population a longer more what's some the ramp which that less and it’s utilization with really genomics maybe a testing through exciting initiatives, all without to undiagnosed oncology before really by in those terms talked frame. NIPT, In lot that of down going areas for us, probably driving expect

Ross Muken

the NextSeq, access key I the derive we obviously talking small, mid MiSeq. early throughput what -- How low whole. is upon about we’re portfolio? access then at if kind And but is its maybe would which end can for of driver driving sequencing lower of thing HiSeq, NIPT has as guess early a what’s but NextSeq, you the should what portfolio, new NIPT to kind any to characterize players how outside been you of before some the seeing touched new do gives And the think been new you part a driving from fleet or as of of a demand it obviously

Sam Samad

pull-through talked its pull-through sometimes at for consumable in maybe talk NextSeq, our range been high-end I’ll and for utilization really the and start guidance on focused NextSeq even clinical its as is your pull-through, for – NextSeq. of well about at the been not NextSeq NextSeq, quickly But exceeding that guidance though range So, with throughput. has And lower on question it very more the about workforce us the space. we’ve

solid So, growth utilization very there. NextSeq very seen on and we’ve

really so the We’ve have most of call lower throughput, desktop exciting On so the the had where recently we HiSeq. MiSeq, some there. we’ve and MiniSeq you that side had what introductions and portfolio, instrument interesting

around on in for and mid recently instance, I for clinical are and for or to utilization accelerate clearance software what the help for side MiSeq, new clinical China was throughput usage MiSeqDx tools in MiSeq analysis seeing XXX MiSeq which question again your Switching received we We’ve clinical back just on days. early and NextSeq the know for will NextSeq. for for enhanced HiSeq discovery. So insights recently we’ve announced practice

general. about me let HiSeq First, in talk

instruments that to cost our those to XX,XXX, XX,XXX period customer either instrument, cost instrument sequenced customers acceptable sequence to never than work of our can less the are expand appeal than for can outsourcing customers starting more sequencing capital benchtop not accessible that because time. they of we with today most the Our have it their appeal that more customers before it to are customers that or can sequencing – base believe and appeal some using first it because are Illumina can it been to

with today have do ahead have these HiSeq, we’ve Illumina pleased What to terms expand or introduction What as are we've seeing with on accessible the and X HiSeq they we expected a in you them that or for that control we’re early runs and significant the instruments NovaSeq and as mean, has of HiSeq are NovaSeq. shipments for customer doing I for they that sequencing mostly base. the you lungs quality applications amount starting error very orders runs. do mean, the so very cost we’re matter, been customers had see, you HiSeq. been using seen, certain When So of HiSeq we’ve potential a on I of basically

of so will doing you goes lot and on failed the the in a an HiSeq. hundreds it you instance cost of NovaSeq a that or them will spare on for dollars drug HiSeq cost And with

So penetrate we’re ultimately those we into I see, applications they start evolve will to talked about. are that starting as customer those other to the applications other segments

Ross Muken

driving each the sort consumer the us research with is of the business that from of few of And the see side. consumer people side, of array been really genomics demand base were it to the where sort kind in you out maybe and of business understand how there’s on it on given sort that the renaissance versus would thought in in of we part business of much where dynamics sort ago of Could And is this be applications? help remarkable, a sort as years reacceleration growing decline. is, traditional tease some

Sam Samad

own yes, overall, get. that – would application arrays mature a would do And I so in portion of would do which out their to is sample. send that of them the consumer and back which consumer. to say have and is like to mean, mostly call other to revenue other the our They is I the and applications to -- we that they more to agrigenomics and send there’s some them. revenues the space, sell send it One results kits get, we revenue, sell but sell some kit. They space which the and do ancestry to customers other get there the space. array testing, process consumer the to lab yes. that them array which the work. part that and components They more some other of to be customers us. in customers services the of is array that related We basically types sent basically XXandMe utilized is consumer consumer. would we be that to it consumables the They instruments We we testing, consumer I Sure, it. consumer to do Then that

of growth the The the of And Obviously consumer rapidly. array of say, last add agrigenomics so business say, has sort quarter of talked in has that's terms year and business. more portion that more the really business been should of we also Last going we mature, that array about consistent been I revenues. significant would I component -- amount… part

Ross Muken

Instrument placement.

Sam Samad

one of significant customer for exactly, ahead the instrument placements particular holiday Yes, season.

that the years were the of the dynamic going number of mentioned sort microarray that space the definitely, that So point samples in samples seven to definitely inflection consumer combined. you in space. previous in What ten first is seen XXXX million in processed of array space, which we’ve in outpaced terms an the the the back

starting is U.S. to seeing we’re expansion to the terms been we’re starting other maybe we’re starting Ross, transition the that but countries well, as in So, that what growth. to see impressive well other very testing. -- it see, transition. It’s as bad very we’re I’m also sure outside we’re so applications, word, can want. resilient. see the and if and well we talk of you see consumer the as been is And not starting And about has very to

Ross Muken

think all customers. a which and key players with I lot of The we of growth as XXXX met expectations elevated. we’re have terms remain hearing recently, we number there, a and consumer, the Luke done the beyond very digging sustainability rates so your in about in of of And for

as own you XXandMe And trial make health. and your the tons So of [Indiscernible], you that discovery. in can around guess applications, that, personal XXandMe socks around clinical my well. develop was a about I of evolution Helix maybe market the something tons enrollment of this genomics I with said, your drug find as there's but tartan now of obviously you to sleep. wife has It initially like color it areas. seems new developing sort sort bit and of for own collaboration of unique consumer the then sort out it's of ancestry of as in things think drive There’s around help and that. push also buying was new Glaxo holidays little using

of So I business confidence much in that that’s will support acceleration the saying are more I certainly the stay, we've of future. sort given higher guess, what I array elevated for but have now to of that rate that mean customers foreseeable as kind you think as a growth about the seen, you duration guess

Sam Samad

growth so said, on. and marketplace can purchase arrays, going this on been you as right? launched I or based want to sequence health I but app apps on a can app. Yes. they I could not could you its impressive far mean would you has say, on they Helix the mean, Genealogy genealogy app genealogy pretty depending been, assesses your with has apps and app, recently through, killer phase. but be And and could be and sequencing to I business plus point, forward health has Those for risk. have affiliate XXandMe Helix we get different collaboration sequence as disease app, just go mail be growth. what key also an information for lifestyle then where about excellent been this the app which get is of based you ancestry definitely an driven like has some think do companies that's going that definitely But which

approval results. So like – for gotten pharmacogenomics have pharmacogenomics. you interactions with FDA might XXandMe that’s also on consumers the Then based how drug release work the the which new what instance And or on to companies other app look have they on like to that have marketplace.

for go nutrigenomics back really is that companies interesting have I as results. Korea release again, see. been South insurance -- to had outside which You with the in Companies to U.S. instance to about like point the well partnered Genoplan expansion

look in like also companies have Australia myDNA that You at releasing pharmacogenomics result.

have a You China. and in recently service collaboration to Kong just China XX with around opened ethnic lab Southeast in have for WeGene they groups in Hong Asia lap setting have genealogy another for us and China that up

So into of outside key expansion health but being other that you’re a aspects, seeing lot things one well. of a of health them, as

Ross Muken

able next business? to there raise year. should into us least that be down We guidance at about XXs. aware about gone was thinking can you've little steady sort the and had a Helix the we’re discussion. that and GRAIL than revenue should will it seems as the more you operating P&L to were all anything obviously we Or a we rate some year? the -- coming outperformed Is for your be of about underlying we’ve think be get talked the about been investment overall. through that compressed period of looking unique just underlying incremental where think margins in there in And we bit a margins to the business as like obviously the in the we investments which drop leverage of the that. through were the you expecting off is of on and many material is may for pretty given this that side of jump separate But PacBio But side how some have in kind

Sam Samad

it It’s so and of together. try lot things sort Yes. of captures the good on a P&L, I’ll it a to question bring

right. You’re

and we structural operating outside report of stock-based low well on. the depending mid-XXs In margin. margins of traditionally in some the as operating used comp this terms We is been of to XXs,

But Now stock-based or exclude target creates bit it you compensation. our if inside been I of so creates some doesn’t operating has traditionally margin. operating would impact – around say impact margin, it a EPS reported we but on XX% XX%

it if impact would significant that investment There this a of structural. catalyzes where to that the be transformative really important of transition, a launching lot as where this either leverage not be platform was is and because decide needs say complementary Our well. brings – an leverage emphasize making in, that is as a approach has been, transient, transformative essentially and investments might year, we bit it new technology investment catalyze. I impact it part that a to market, listen, Because more make certain we technology and I -- there we’re we as of new to could we’re that's in years, this is are market it as necessary Illumina decide transition might opportunity going investments this the the we points we or

of with that and some had we’ve Helix. the about initiatives GRAIL even You talked

we because that I investments committed are those we see deviations make. So, that to there of say some of would be we definitely could transformative Overall leverage.

margin that depending short earlier, in could be could target on our mentioned time but committed to impact it it operating We’re frame that. transient, I have

Ross Muken

color, the areas, large give of Could you so Just of getting of little given mean, How complexity right? the underlying. a just bit us is what I the R&D them. really so sort sort is in about many of now, you think of you've budget entered of some

sort of things of one what think Illumina, lot a money. company of analyze when I look tough they obviously spending a at can we quite we like those know, you’re but

iterations transformative than of of lot terms think we lower risk was in to the versus of you sort the a of of degree some there’s these not sort on budget, to of that risk something investments just existing which architecting underlying. how but about not know going So be a portfolio GRAIL don't may higher or

a approach Just it? flavor philosophical the give of in of part us for kind

Sam Samad

and is your have pipeline also Yes. return things parts toughest my able of exciting you the going because to job, sure back at R&D to on. same Probably much the that what one investing shareholders, but how is to going many on, of balancing you’re so which do your we time there's make exciting need so in be you so

great the and there comparable Ross, peer out say. invested that we've our of And So to a of about $XXX just is architecture. said we XX% of example that in or day I path lot our going going it to in existing evolve that R&D that have be of captured space. NovaSeq the architecture sector lot definitely The that the of or over years the to and because of topline would that in R&D about traditionally towards a us a genome we some to architectures that evolving I the us players next the which and get talked that's players R&D exceeding to how that’s is get you’ve go to companies architecture $XXX well, is existing portion the genome we and few think your around investments we’ve can pipeline is this point lot

new you other the architectures innovations the you of did get portion also on or the some we another which have and -- we but strategic next necessarily is the then and is parts platforms develop Another have. new do pipeline piece the then of our would innovations another long-term And more that development R&D in the piece same around and to maybe the pipeline level, that how that call though in not nature. more investments that much pie us looks you which are at I and also have research of around say what technology

most job for going mission for patients customers, extremely most are improving really our focused us meaningful my on aligned how those our be execute. And health that we compartmentalized it’s very we So to way. things to be How to that human our and be of disciplined that force are at to really is look prioritize R&D. on how the we

Ross Muken

have seconds few we guess And lastly, left. I

spread next You to in maybe conference major sort to that, aside. typically can competitor around, year but is and have the just put time this maybe you close pieces just announce of used let’s enough that venue

mix as sort about it’s where your how can now guess you’re you of top new kind of everything? application of new mind the leading the sort about guess kind movers biggest of or sort we off sort of some I are needle you of right of investment As areas I thinking and piece. different of the of from thinking think different versus still how for just other a of functions, versus software platform prioritizing what of R&D bit come about of

Sam Samad

the commitment. portion work do you mean discipline then of an towards commitment throughput, have in architecture low we that I we sequencing, out would we before, and it’s it's know Yes. sure Sure. the to that -- the carving are to have towards, say that we high mid-throughput platforms, develop commitment whether a or new we investments because a said of we’re we cost continue I to then making new a of reduce innovations I that again R&D to have and knowledge going throughput allocated But we’ll space. as have also

Ross Muken

Well, thanks Sam, Jacquie, Excellent. for coming.

You exciting always make it for us.

great So, we on look things and story an the in hear always forward great from hearing to to update everybody. XXXX. you Thanks

Sam Samad

Ross. you, it. Appreciate Thank Thanks everyone.

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.